Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-650

MSB doesn't have any say in the speed of the Covid-19 ARDS trial recruitment. Although now there are more covid cases and more patients on ventilators, the big issue is hospitals are overwhelmed by the situation. Not enough medical personnel to cope. We know for every patient in the trial there is a procedure to follow (max 3 days on a ventilator, blood sample, obtaining consent, other tests, reticency to stem cells, etc) that will involve few people in the yard to collect all this data. Plus the max quota of patients in the trial for every hospital/center and other parallel trials. It is not so easy as some people believe or hope, SI included. So close now, you can feel it, Novartis on board as well. Amazing job on MSB part.